Xinhua Pharmaceutical: Obtained Enetacapone tablets drug registration certificate.

Xinhua Pharmaceutical announced that the company recently received the "Drug Registration Certificate" for Entacapone tablets issued by the National Medical Products Administration. This drug is a prescription drug that can assist in the treatment of Parkinson's disease and end-of-dose phenomena, and it is classified as a category B variety in the medical insurance catalog. In 2024, the sales of this drug in public medical institutions in China are expected to be approximately 286 million yuan. This approval enriches the company's formulation product series, enhances overall competitiveness, but drug sales are subject to uncertainties due to factors such as policies and market conditions.